Dr. Wong Seng Weng, MBBS, MRCP(UK), FAMS (Medical Oncology)

Dr. Wong Seng Weng, MBBS, MRCP(UK), FAMS (Medical Oncology)

Medical Director & Consultant Medical Oncologist 
The Cancer Centre (Singapore Medical Group) 
Paragon Medical & Mt Elizabeth Novena 
Specialist Centre Visiting Consultant 
Mt Elizabeth Hospital & Mt Elizabeth Novena Hospital 
Adjunct Clinician Scientist 
Institute of Bioengineering & Nanotechnology (IBN)
Agency for Science, Technology & Research (A*STAR) 
Singapore

Related Videos

What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine? Video

What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine?

What is your current guidance about whether and/or how and when to integrate tests for circulating tumor DNA (ctDNA) into protocols for precision cancer medicine?

Can you give an example of a patient in which the failure to initially deploy, but subsequent use of NGS-based, comprehensive molecular profiling led to improvements in their clinical course? Video

Can you give an example of a patient in which the failure to initially deploy, but subsequent use of NGS-based, comprehensive molecular profiling led to improvements in their clinical course?

Can you give us a specific example of a patient in which the failure to initially deploy, but then subsequent use of NGS-based, comprehensive molecular profiling led to documented improvements in their clinical course based on identification of targeted agent?

What did we learn from the SHIVA Trial and how might the "disappointing" results of this trial have been misinterpreted, thereby underestimating the potential benefits of targeted therapy? Video

What did we learn from the SHIVA Trial and how might the "disappointing" results of this trial have been misinterpreted, thereby underestimating the potential benefits of targeted therapy?

What did we learn from the SHIVA Trial and in what ways might the “disappointing” results of this trial have been misinterpreted, thereby underestimating the potential benefits of targeted therapy?

When in the course of diagnosis and history does whole exome, hybrid capture NGS sequencing fit into the diagnostic roadmap for identifying targeted therapies? How does NGS compare to hot spot testing? Video

When in the course of diagnosis and history does whole exome, hybrid capture NGS sequencing fit into the diagnostic roadmap for identifying targeted therapies? How does NGS compare to hot spot testing?

When exactly, in the course of a patient’s cancer diagnosis and history, does whole exome, hybrid capture NGS sequencing fit into the diagnostic roadmap for the purpose of identifying targeted therapies? And how do the capabilities of ...

What are the implications of FDA approval of PD-1 inhibitors across a broad spectrum of mismatch repair-deficient tumors? What are the implications for NGS-based molecular diagnostics? Video

What are the implications of FDA approval of PD-1 inhibitors across a broad spectrum of mismatch repair-deficient tumors? What are the implications for NGS-based molecular diagnostics?

What are the implications of the FDA having approved PD-1 inhibitors across a broad spectrum of mismatch repair-deficient tumors? And what are the implications for NGS-based molecular diagnostics?